Table 2 Treatment-emergent adverse events (AEs) by preferred term
GLP-1-RA group (n = 13) | |
|---|---|
Any AEs | 9 (69.2) |
Mild AEs | 1 (7.7) |
Moderate AEs | 8 (61.5) |
Severe AEs | 0 (0.0) |
AEs leading to premature treatment discontinuation | 0 (0.0) |
AEs occurring in \(\ge\) 5% of patients | |
Nausea | 9 (69.2) |
Mild | 1 (7.7) |
Moderate | 8 (61.5) |
Decreased appetite | 2 (15.4) |
Increased lipase | 3 (23.1) |
Mild (< 1.5 ULN) | 3 (23.1) |
Diarrhea | 1 (7.7) |
Mild | 1 (7.7) |
Hypoglycemia | 1 (7.7) |
Mild (55–70 mg/dL) | 1 (7.7) |
Increased ALAT | 1 (7.7) |
Mild (< 3.0 ULN) | 1 (7.7) |
Dyspepsia | 1 (7.7) |
Mild | 1 (7.7) |